Optiscan completes beta phase telepathology development

Confocal microscopy manufacturer Optiscan Imaging has completed the beta phase development of its cloud-connected telepathology platform developed in partnership with Prolucid Technologies.

The development is a significant advancement in digital pathology, according to the company, enabling real-time, remote collaboration on patient imaging sessions.

The platform utilises Optiscan’s confocal imaging technology to generate digital pathology data, with the telepathology platform allowing remotely located pathologists and clinicians to view live images and collaborate during patient imaging sessions.

Optiscan CEO and Managing Director Dr. Camile Farah said: “This achievement makes the platform a potential game changer for telehealth consultations for patients who live outside of capital city areas.

“In the past, regional, rural and remote health facilities have lacked the dedicated pathology expertise limiting collaboration and immediate decision-making between clinicians and pathologists.

“Our platform provides a way for isolated communities to tap into pathology expertise previously not available to them due to limited medical infrastructure or difficulties in attracting health care professionals.”

Key deliverables in the beta phase included the ability to register, authenticate, and securely connect devices to the cloud platform.

According to Optiscan its collaborative approach facilitates immediate, informed decision-making at the point of care, ultimately improving patient outcomes.

At the patient’s side, Optiscan’s device captures real-time confocal images and transmits them securely to the cloud platform.

The platform streamlines the telepathology workflow with secure device-to-cloud connectivity and a dedicated web portal.

Dr Farah said: “Our telepathology-enabled imaging solutions democratise pathology services and high quality patient care.”

“With the successful beta testing phase complete, we have already ramped up efforts to create a commercial version of our telepathology platform and now look forward to its implementation in clinical settings.

“Our aim is to initially implement a minimal viable telepathology platform, with further enhancements and features to be developed in subsequent phases.”

User authentication, data transmission latency, patient privacy protection, data encryption, synchronization, and management have been implemented, ensuring compliance with stringent cybersecurity requirements, according to Optiscan.

Further reading:
Browse @AuManufacturing’s coverage of Optiscan Imaging here.

Picture: Optiscan Imaging